FOR HEALTHCARE PROFESSIONALS ONLY

Tryngolza® (olezarsen) 80 mg injection

Tryngolza™ (olezarsen)

The only treatment for familial chylomicronemia syndrome (FCS) delivered via a prefilled autoinjector[1]

A targeted apolipoprotein C-III (apoC-III) inhibitor shown to effectively and consistently lower triglyceride levels[1,2]

Provided an 88% reduction in the incidence of acute pancreatitis over 1 year compared to placebo[*1,2]

Indicated as an adjunct to diet in adult patients for the treatment of genetically confirmed FCS[1]

There are several requirements for the proper use of Tryngolza in accordance with the product information, which are summarised in the checklist below.

Checklist: Tryngolza initiation assessment

- ☐ **Genetically confirmed FCS**
  FCS is caused by genetic defects leading to deficient LPL activity. Genes associated with FCS include *LPL*, *APOA5*, *APOC2*, *GPIHBP1*, and *LMF1*; other genes have been proposed, such as *CREB3L3 and GPD1*, and others may be identified in the future.[3–5]
- ☐ **New treatment regimen discussed**
  (for new patients and those being switched from Waylivra [volanesorsen])
- ☐ **Patient aware/informed that a very low-fat diet is still required**
  - Tryngolza is an adjunct to dietary management of FCS
- ☐ **Dosing and administration discussed:[1]**
  - ☐ 80 mg administered once a month as a subcutaneous injection using a pre-filled autoinjector
  - ☐ In accordance with the instructions for use, patients can inject the medicine themselves (under the skin on the abdomen or front of the thigh); a healthcare provider or caregiver may administer the injection in the back of the upper arm
  - ☐ It should not be injected into skin that is bruised, tender, red, or hard, into scars or damaged skin; the area around the navel should be avoided

Tryngolza▼ (olezarsen) 80 mg injection

Useful links

Tryngolza product information:
https://www.ema.europa.eu/en/documents/product-information/tryngolza-epar-product-information_en.pdf

Further information on familial chylomicronemia syndrome:
https://pro.sobi.com/en/therapeutic-areas-diseases/specialty-care/fcs

*Mean rate ratio (pooled 80 mg and 50 mg olezarsen groups vs. placebo): 0.12; 95% CI 0.02 to 0.66[1,2]

References

1. Tryngolza EU Summary of Product Characteristics. December 2025.
2. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al; Balance Investigators. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. *N Engl J Med*. 2024;390(19):1781–1792.
3. Bashir B, et al. Severe hypertriglyceridaemia and chylomicronaemia syndrome—causes, clinical presentation, and therapeutic options. *Metabolites* 2023;13:621. https://doi.org/10.3390/metabo13050621.
4. Matarazzo L, Ragnoni V, Malaventura C, et al. Successful fenofibrate therapy for severe and persistent hypertriglyceridemia in a boy with cirrhosis and glycerol-3-phosphate dehydrogenase 1 deficiency. *JIMD Rep*. 2020;54(1):25-31.
5. Hegele R, Boren J, Ginsberg H, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. *Lancet Diabetes Endocrinol*. 2020;8:50–67.

Tryngolza▼(olezarsen) is indicated as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS).

▼This medicinal product is subject to **additional monitoring**. This will allow quick identification of new safety information. See section 4.8 of the SmPC for how to report adverse reactions.

Tryngolza SmPC:

Healthcare professionals should report any suspected adverse reactions via their national pharmacovigilance reporting system. Suspected adverse reactions should also be reported to Sobi via email at drugsafety@sobi.com.

This material is intended for an international audience of healthcare professionals and is based on the Tryngolza Summary of Product Characteristics (SmPC) approved for use in the European Economic Area (EEA). SmPC/Prescribing information, product availability, and pricing/reimbursement conditions may vary by country. Before prescribing, always refer to locally approved SmPC and/or prescribing information.

The Sobi Scientific Information Department is at your disposal for any additional information: medical.info@sobi.com.

PP-33235-TRG-COMM-GLO-SobiPro May 2026

sobi